The Administrative Core will provide central leadership and management for the Oklahoma Autoimmunity Center of Excellence (Oklahoma ACE) to expedite translation of basic science advances to clinical application in the diagnosis and treatment of systemic autoimmune diseases. Coordinating the efforts of key participants from adult and pediatric rheumatology, adult and pediatric endocrinology, neurology, hematology, dermatology, dentistry, ophthalmology, and a variety of basic science disciplines such as various types of immunology, molecular biology, genetics, biostatistics, and epidemiology will be one of the central missions of this Core. Providing unique trans-disciplinary opportunities to discuss translational autoimmune disease research through the Autoimmunity Forums, as well as coordinating participation in ACE led clinical trials will be the focus of this Oklahoma ACE. These tasks will include (i) acting on behalf of the Oklahoma ACE member institutions, and within the ACE Network and NIH Program, (ii) ensuring fiscal responsibility for all components of the ACE, and (iii) providing an educational foundation for a multidisciplinary approach to autoimmune disease research. The Administrative Core Leader will perform the daily management tasks, host monthly Autoimmunity Forums, and facilitate annual EAB meetings. The Core Leader will also meet monthly with the Clinical Representative to ensure the Clinical Center needs are being met. The Core Leader will serve as the primary contact within the ACE Network and with the assistance of the Clinical Representative coordinate sample distribution both within the Oklahoma ACE community and the ACE Network. The Core Leader and Clinical Representative will attend ACE Steering Committee meetings. The Core Leader will also be the primary contact for the NIH ACE Program. She will be responsible for preparing and submitting all annual progress reports, and just-in-time and other information as needed to the NIH. Through the assistance of the OMRF grants accounting office, the Core Leader will also be responsible for managing the Oklahoma ACE budget. These services provided by the Administrative Core will optimize use of the funding to ensure the Oklahoma ACE goals are met in a timely manner.
The Oklahoma ACE community is a multidisciplinary team of clinician scientists and basic science investigators with the common goal of improving the lives of patients with systemic autoimmune diseases through expediting the translation of basic science findings to clinical applications. The Administrative Core will provide the central leadership and management to the Oklahoma ACE community.
|Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247|
|Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531|
|Jog, Neelakshi R; Chakravarty, Eliza F; Guthridge, Joel M et al. (2018) Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Front Immunol 9:2198|
|Fu, Yao; Tessneer, Kandice L; Li, Chuang et al. (2018) From association to mechanism in complex disease genetics: the role of the 3D genome. Arthritis Res Ther 20:216|
|Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824|
|Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :|
|Wang, Chih-Chuan; Ortiz-González, Xilma R; Yum, Sabrina W et al. (2018) ?IV Spectrinopathies Cause Profound Intellectual Disability, Congenital Hypotonia, and Motor Axonal Neuropathy. Am J Hum Genet 102:1158-1168|
|Scofield, R Hal; Sharma, Rohan; Harris, Valerie M (2018) Reply. Arthritis Rheumatol 70:626-627|
|Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307|
|St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480|
Showing the most recent 10 out of 133 publications